# Preventice Solutions

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/preventice-solutions

- Industry: Healthcare IT
- Headquarters: Houston, US
- Website: www.preventicesolutions.com
- Total disclosed funding: $45M
- Latest round: Series B (Jul 10, 2020)
- Investors on record: 5

## About

Preventice Solutions, Inc. is a healthcare technology company specializing in advanced cardiac monitoring solutions that facilitate remote patient management and improve cardiovascular care through innovative devices.Founded in 2004 and headquartered in Houston, US, Preventice Solutions, Inc. focuses on developing advanced cardiac monitoring technologies. The company was acquired by Boston Scientific Corporation in November 2020 for approximately USD 925 mn, following investments from notable entities like the Merck Global Health Innovation Fund and Novo Holdings A/S. Jon Otterstatter serves as the CEO, leading the company after its strategic acquisition. Preventice Solutions has initiated three significant deals to date, with the latest deal occurring on November 30, 2020.Preventice Solutions, Inc. specializes in advanced cardiac monitoring solutions through its flagship products, BodyGuardian™ MINI and BodyGuardian™ MINI PLUS. These wearable monitors are designed for continuous use, allowing patients to wear them comfortably and securely 24/7. They facilitate remote ECG data collection, providing healthcare professionals with critical insights for diagnosing cardiovascular conditions. The devices are compatible with various electronic medical record (EMR) systems, ensuring seamless integration and communication between patients and healthcare providers. The company caters to a diverse client base, including hospitals and outpatient centers, primarily in the United States and Europe.The revenue model of Preventice Solutions is primarily based on direct sales and partnerships involving its cardiac monitoring devices. The company engages in B2B transactions with healthcare institutions that utilize the BodyGuardian products for patient monitoring, typically through subscription models and direct sales. Clients acquire the monitors along with associated services like analytics and integration support, with pricing structured to accommodate a variety of healthcare settings, ensuring broad accessibility.In light of the acquisition by Boston Scientific Corporation, Preventice Solutions plans to leverage the recent funding to enhance its product offerings and market presence. The company is focused on developing new iterations of the BodyGuardian products, with plans for expansion into additional markets across Europe and Asia by 2023. The strategic investment will support initiatives aimed at improving the functionality and integration of monitoring solutions within healthcare systems, ensuring that both patients and providers benefit from advanced cardiac care technologies.

## Funding rounds

- Series B, Jul 10, 2020, $45M — Vivo Capital, Merck Global Health Innovation Fund, Novo Holdings, Boston Scientific Corporation, Samsung Strategy & Innovation Center

## Investors

- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series B
- Novo Holdings — Series B
- Boston Scientific Corporation — Series B
- Samsung Strategy & Innovation Center (https://capitalatlas.ai/funds/samsung-strategy-innovation-center) — Series B